A recent review highlights inflammation’s dual role in cancer progression and how emerging tools like AI and imaging biomarkers are enhancing personalized immunotherapy.
Key Details
- 1Chronic inflammation promotes tumorigenesis, survival, and therapy resistance, but can also suppress cancer depending on context.
- 2Key pathways: NF-κB, STAT3, IL-6, COX-2, and specific immune cells modulate the tumor microenvironment.
- 3Immunotherapies show varying efficacy (20–40% response rates); biomarkers like CRP, IL-6, and imaging data are key for patient stratification.
- 4Combination strategies (immunotherapy plus anti-inflammatories or microbiome modulators) are under clinical investigation.
- 5AI models incorporating imaging and multi-omic data are enabling real-time treatment personalization; Stanford’s 2024 model integrates imaging/text.
- 6Emerging tools include liquid biopsies, single-cell omics, gene editing, and nanotechnology for more precise disease monitoring.
Why It Matters
Understanding how inflammation drives cancer and therapy resistance is crucial for radiology, especially as integration of imaging, AI, and novel biomarkers underpins the move toward precision oncology. These advances offer new avenues for diagnosis, patient stratification, and monitoring treatment response using imaging and AI-driven tools.
Source
EurekAlert
Related News
•EurekAlert
UVA's $4M NIH Grant Backs AI to Optimize Cardiac MRI Therapies
UVA secures $4 million NIH funding to develop GenStrain, an AI model using MRI data to personalize cardiac pacing therapies.
•EurekAlert
Machine Learning Models Predict Cancer Risk with Routine Health Data
Researchers developed machine learning models using routinely collected health data to predict individual risk for 20 common cancers, outperforming traditional methods for several cancer types.
•EurekAlert
Duke Receives $25M to Lead National Trustworthy AI Hub for Dementia and Aging
Duke University has launched a $25 million national center to make AI for aging and dementia clinically robust and trustworthy.